IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kidney disease: BHV-1400 trial targets protein leak
Disease control Not yet recruitingThis study tests whether BHV-1400 can safely reduce kidney damage in people with IgA nephropathy, a disease where antibodies build up in the kidneys. About 420 adults with confirmed IgA nephropathy and high protein in their urine will be randomly assigned to receive either BHV-14…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 16, 2026 22:34 UTC
-
New hope for kidney disease: experimental drug targets protein leak
Disease control Not yet recruitingThis early-stage trial tests a drug called NM8074 in 10 adults with IgA Nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug safely reduces protein in the urine, a sign of kidney damage, after 99 days of treatment. Participants must have a…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: NovelMed Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New injection shows promise for kidney disease in early trial
Disease control Not yet recruitingThis study tests a new drug, CM313, in 106 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and helps control the disease. Participants must have had a kidney biopsy confirming the disease and be on standard care. The study is not yet recruiti…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New hope for kids with rare kidney disease: drug trial targets protein leak
Disease control Not yet recruitingThis study tests a drug called atrasentan in 28 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage, over 36 weeks. Participants will take the drug …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 03, 2026 12:06 UTC
-
Can a longer treatment keep kidney disease in remission?
Disease control Not yet recruitingThis study tests whether taking Nefecon for 15 months can prevent proteinuria (protein in urine) from returning in people with IgA nephropathy who have already responded to treatment. About 288 adults who have completed 9 months of Nefecon and have low protein levels will be rand…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE4 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 03, 2026 12:03 UTC
-
New study tracks kidney patients on two promising drugs
Knowledge-focused Not yet recruitingThis study will follow about 80 adults with IgA nephropathy, a kidney disease, who are starting treatment with either iptacopan or atrasentan. Researchers will collect information on patients' health, treatments, and outcomes over two years to see how these drugs work in everyday…
Matched conditions: IGA NEPHROPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 11, 2026 12:10 UTC